Recurrent non small cell lung cancer
Clinical trials for Recurrent non small cell lung cancer explained in plain language.
Never miss a new study
Get alerted when new Recurrent non small cell lung cancer trials appear
Sign up with your email to follow new studies for Recurrent non small cell lung cancer, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New immunotherapy cocktail aims to boost lung cancer survival
Disease control CompletedThis phase 2 trial tested whether adding relatlimab to the standard immunotherapy nivolumab plus chemotherapy could shrink tumors better in people with advanced or recurrent non-small cell lung cancer. About 468 participants received either the two-immunotherapy combo with chemo …
Matched conditions: RECURRENT NON SMALL CELL LUNG CANCER
Phase 2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New combo therapy shows promise for Hard-to-Treat lung cancer
Disease control CompletedThis early-phase study tested a new drug called ONO-7475 combined with the standard targeted therapy osimertinib in 78 people with advanced EGFR-mutated non-small cell lung cancer. The goal was to see if the combination is safe and tolerable. Participants had stage IIIB, IIIC, IV…
Matched conditions: RECURRENT NON SMALL CELL LUNG CANCER
Phase 1 • Sponsor: Ono Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New drug duo targets lung cancer brain metastases
Disease control CompletedThis phase 2 trial tested two drugs, amivantamab and lazertinib, in 43 adults with a specific type of lung cancer (EGFR-mutant) that had spread to the brain and worsened after previous treatments. The goal was to see if the combination could shrink or control brain tumors. Both d…
Matched conditions: RECURRENT NON SMALL CELL LUNG CANCER
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC